

Moderna Clinical Trials Terribly Flawed — and FDA Knew It, Former Pharma Executive Tells RFK, Jr.

By Rachel Militello

Region: <u>USA</u>

Global Research, August 10, 2022

Theme: Intelligence, Science and Medicine

Children's Health Defense 9 August 2022

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), click here.

Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

There were "terrible flaws" in Moderna's <u>COVID-19</u> vaccine clinical trials — and the U.S. Food and Drug Administration (FDA) knew it, according to Alexandra Latypova, a former pharmaceutical industry executive who reviewed nearly 700 pages of documents Moderna submitted to the FDA as part of its application process.

Latypova, who has 25 years of experience in pharmaceutical research and development, started a number of successful companies — primarily focused on creating and reviewing clinical trials.

On a recent episode of "RFK Jr. The Defender Podcast," she told Kennedy what she learned after reviewing the Moderna documents, obtained via a Freedom of Information Act request.

Latypova told Kennedy that out of nearly 700 pages, about 400 pages are irrelevant studies that Moderna repeated multiple times.

Moderna also submitted three versions of a single module, she said. And one module contained only narrative summaries of Moderna's studies, but no actual study results.

"So we are still missing a large number of results, such as full reports that are supporting those narratives," Latypova told Kennedy.

The FDA "obviously did not object" to any of this, she said. "That's <u>evidence of collusion</u> to me with the manufacturer."

Latypova also discussed Moderna's clinical trials timeline. She said the Investigational New Drug (IND) application meeting is supposed to occur with the FDA when the company initiates human clinical trials.

Moderna and the FDA had a pre-IND meeting on Feb. 19, 2020, and the IND application was

formally opened the next day. The global pandemic was declared on March 11, 2020.

"Somehow these visionaries could predict the future with such certainty that they opened a clinical trial for the vaccine, for which a pandemic was announced a month later," Latypova said.

There is normally only one IND application for one product. In this case, however, there are two IND applications — one belonging to Moderna, and one belonging to the National Institutes of Health, which <u>partnered</u> with Moderna on its COVID-19 vaccine.

Latypova also told Kennedy that Moderna did not conduct studies to determine if its mRNA vaccine affected male fertility.

"We have no idea what [the vaccine] does to young men who want to have children in the future." she said.

The documents also confirm that Moderna's trials studied the vaccine's delivery mechanism, but not its payload, which in this case is the <u>spike protein</u>.

"They want you to believe that ... you can ... have a truck filled with food, or you can have a truck filled with explosives," Latypova said. "They're saying it doesn't matter. Focus on the truck. It's the same truck, doesn't matter what's inside."

In the end, Latypova said,

"They're desperate to vaccinate every single person on the planet because they don't want you to know what's going on."

Watch the episode here.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Rachel Militello has worked extensively as a legal assistant at law firms and newspaper companies. She is also a self-published author of poetry that is geared toward mental health awareness.

Featured image is from CHD

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Rachel Militello</u>, <u>Children's Health Defense</u>, 2022

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Rachel Militello

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca